461 related articles for article (PubMed ID: 7539660)
1. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.
Robertson MJ; Manley TJ; Pichert G; Cameron C; Cochran KJ; Levine H; Ritz J
Leuk Lymphoma; 1995 Mar; 17(1-2):51-61. PubMed ID: 7539660
[TBL] [Abstract][Full Text] [Related]
2. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A; Villunger A; Marschitz I; Kos M; Hittmair A; Lukas P; Grünewald K; Greil R
Br J Haematol; 1997 May; 97(2):418-28. PubMed ID: 9163609
[TBL] [Abstract][Full Text] [Related]
3. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas.
Kondo E; Yoshino T; Yamadori I; Matsuo Y; Kawasaki N; Minowada J; Akagi T
Am J Pathol; 1994 Aug; 145(2):330-7. PubMed ID: 7519826
[TBL] [Abstract][Full Text] [Related]
4. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines.
Dirks W; Schöne S; Uphoff C; Quentmeier H; Pradella S; Drexler HG
Br J Haematol; 1997 Mar; 96(3):584-93. PubMed ID: 9054667
[TBL] [Abstract][Full Text] [Related]
7. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells.
Karawajew L; Wuchter C; Ruppert V; Drexler H; Gruss HJ; Dörken B; Ludwig WD
Leukemia; 1997 Aug; 11(8):1245-52. PubMed ID: 9264377
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders.
Hata H; Matsuzaki H; Takeya M; Yoshida M; Sonoki T; Nagasaki A; Kuribayashi N; Kawano F; Takatsuki K
Blood; 1995 Sep; 86(5):1939-45. PubMed ID: 7544648
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.
Panayiotidis P; Ganeshaguru K; Foroni L; Hoffbrand AV
Leukemia; 1995 Jul; 9(7):1227-32. PubMed ID: 7543175
[TBL] [Abstract][Full Text] [Related]
11. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.
Weller M; Malipiero U; Aguzzi A; Reed JC; Fontana A
J Clin Invest; 1995 Jun; 95(6):2633-43. PubMed ID: 7539458
[TBL] [Abstract][Full Text] [Related]
12. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
13. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression.
Mapara MY; Bargou R; Zugck C; Döhner H; Ustaoglu F; Jonker RR; Krammer PH; Dörken B
Eur J Immunol; 1993 Mar; 23(3):702-8. PubMed ID: 7680614
[TBL] [Abstract][Full Text] [Related]
14. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness.
Owen-Schaub LB; Radinsky R; Kruzel E; Berry K; Yonehara S
Cancer Res; 1994 Mar; 54(6):1580-6. PubMed ID: 7511047
[TBL] [Abstract][Full Text] [Related]
15. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.
Shima Y; Nishimoto N; Ogata A; Fujii Y; Yoshizaki K; Kishimoto T
Blood; 1995 Feb; 85(3):757-64. PubMed ID: 7530506
[TBL] [Abstract][Full Text] [Related]
16. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program.
Debatin KM; Krammer PH
Leukemia; 1995 May; 9(5):815-20. PubMed ID: 7539514
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Zhou M; Gu L; Yeager AM; Findley HW
Leukemia; 1998 Nov; 12(11):1756-63. PubMed ID: 9823951
[TBL] [Abstract][Full Text] [Related]
18. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
19. [Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma].
Sasao T; Yoshida M; Ichikawa Y
Nihon Rinsho; 1996 Jul; 54(7):1986-91. PubMed ID: 8741700
[TBL] [Abstract][Full Text] [Related]
20. Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes.
Yoshino T; Kondo E; Cao L; Takahashi K; Hayashi K; Nomura S; Akagi T
Blood; 1994 Apr; 83(7):1856-61. PubMed ID: 7511441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
